Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

Introduction First-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
treatment of advanced non–small-cell lung cancer with EGFR-activating mutations improves …

Background Although the epidermal growth factor receptor (EGFR) inhibitor erlotinib is
initially effective in non–small-cell lung cancer (NSCLC) patients with tumors harboring …

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-
cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or …

Patients with non-small cell lung cancer (NSCLC) who have activating epidermal growth
factor receptor (EGFR) mutations benefit from treatment with EGFR-tyrosine kinase inhibitors …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Epidermal growth factor receptor (EGFR) is a transmembrane receptor with a cytoplasmic
tyrosine kinase (TK) domain present on many solid tumors including non-small cell lung …

Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Lung cancer is primarily diagnosed during the advanced stage of disease, at which stage
treatment options are severely limited. It is primarily for this reason that lung cancer carries a …

The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …